- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06863272
Een klinische studie van op ifinatamab deruxteecan gebaseerde behandelingscombinaties of als monotherapie om metastatisch castratresistente prostaatkanker (MCRPC) (MK-2400-01A/Ideate-prostate02) te behandelen)
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
-
La Rioja, Argentinië, F5300COE
- Werving
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
Contact:
- Study Coordinator
- Telefoonnummer: 54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentinië, C1426ANZ
- Werving
- Instituto Alexander Fleming ( Site 0202)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5411 3221 8900
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australië, 2109
- Werving
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61 2 9812 2956
-
-
-
-
-
São Paulo, Brazilië, 01221-020
- Werving
- IPITEC ( Site 0275)
-
Contact:
- Study Coordinator
- Telefoonnummer: +551194322-6006
-
São Paulo, Brazilië, 03102-006
- Werving
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
Contact:
- Study Coordinator
- Telefoonnummer: +551144500360
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazilië, 59062-000
- Werving
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
Contact:
- Study Coordinator
- Telefoonnummer: (84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90035-001
- Werving
- Hospital Moinhos de Vento ( Site 0278)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 51 3314-3209
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90020-090
- Werving
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
Contact:
- Study Coordinator
- Telefoonnummer: +555132148151
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brazilië, 12916-542
- Werving
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
Contact:
- Study Coordinator
- Telefoonnummer: +551124901366
-
Ribeirão Preto, São Paulo, Brazilië, 14048900
- Werving
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
Contact:
- Study Coordinator
- Telefoonnummer: (16) 3963-6487
-
São José do Rio Preto, São Paulo, Brazilië, 15090-000
- Werving
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
Contact:
- Study Coordinator
- Telefoonnummer: +55 17 99625-3919
-
São Paulo, São Paulo, Brazilië, 01327-001
- Werving
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
Contact:
- Study Coordinator
- Telefoonnummer: 55 11 3549-0009
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Werving
- BC Cancer - Vancouver Center ( Site 0103)
-
Contact:
- Study Coordinator
- Telefoonnummer: 6048776000
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Sunnybrook Research Institute ( Site 0109)
-
Contact:
- Study Coordinator
- Telefoonnummer: 4164806100
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- Princess Margaret Cancer Centre ( Site 0102)
-
Contact:
- Study Coordinator
- Telefoonnummer: 4169464501
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Werving
- Jewish General Hospital ( Site 0108)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5143408110
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Werving
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
Contact:
- Study Coordinator
- Telefoonnummer: 8197802222
-
-
-
-
Maule Region
-
Talca, Maule Region, Chili, 3465584
- Werving
- Clinica Universidad Catolica del Maule ( Site 0236)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56992992913
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 8420383
- Werving
- Bradfordhill ( Site 0231)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56229490970
-
Santiago, Region M. de Santiago, Chili, 7560908
- Werving
- Centro de Oncología de Precisión ( Site 0241)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56225189885
-
Santiago, Region M. de Santiago, Chili, 7500921
- Werving
- Fundación Arturo López Pérez ( Site 0232)
-
Contact:
- Study Coordinator
- Telefoonnummer: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chili, 2520598
- Werving
- ONCOCENTRO APYS ( Site 0234)
-
Contact:
- Study Coordinator
- Telefoonnummer: +56323320850
-
-
-
-
-
Hamburg, Duitsland, 20246
- Werving
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Duitsland, 69120
- Werving
- NCT ( Site 0528)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00496221566857
-
Ulm, Baden-Wurttemberg, Duitsland, 89081
- Werving
- Universitaetsklinikum Ulm. ( Site 0530)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4973150058188
-
-
Thuringia
-
Jena, Thuringia, Duitsland, 07747
- Werving
- Universitaetsklinikum Jena ( Site 0525)
-
Contact:
- Study Coordinator
- Telefoonnummer: +49-3641-9-329901
-
-
-
-
Gironde
-
Bordeaux, Gironde, Frankrijk, 33000
- Werving
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33556333261
-
-
Nord
-
Lille, Nord, Frankrijk, 59000
- Werving
- Centre Oscar Lambret ( Site 0495)
-
Contact:
- Study Coordinator
- Telefoonnummer: +333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Frankrijk, 44800
- Werving
- Institut De Cancerologie De L Ouest ( Site 0494)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne, Pyrenees-Atlantiques, Frankrijk, 64100
- Werving
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33559443762
-
-
Rhone
-
Pierre-Bénite, Rhone, Frankrijk, 69310
- Werving
- centre hospitalier lyon sud ( Site 0497)
-
Contact:
- Study Coordinator
- Telefoonnummer: 33 4 78 86 43 24
-
-
-
-
-
Dublin, Ierland, D09 V2N0
- Werving
- Beaumont Hospital, Dublin ( Site 0465)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0035318092010
-
Dublin, Ierland, D24 NR0A
- Werving
- Tallaght University Hospital ( Site 0462)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0035314144209
-
-
Dublin
-
Dublin, Dublin, Ierland, D04 T6F4
- Werving
- St Vincent's University Hospital ( Site 0463)
-
Contact:
- Study Coordinator
- Telefoonnummer: +353 1 221 4982
-
-
-
-
-
Haifa, Israël, 3109601
- Werving
- Rambam Health Care Campus ( Site 0400)
-
Contact:
- Study Coordinator
- Telefoonnummer: 972(47776234)
-
Jerusalem, Israël, 9112001
- Werving
- Hadassah Medical Center ( Site 0404)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97226777333
-
Petah Tikva, Israël, 4941492
- Werving
- Rabin Medical Center ( Site 0402)
-
Contact:
- Study Coordinator
- Telefoonnummer: +972544594048
-
Ramat Gan, Israël, 5265601
- Werving
- Sheba Medical Center ( Site 0401)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97235303030
-
Tel Aviv, Israël, 6423906
- Werving
- Sourasky Medical Center ( Site 0403)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97236947832
-
-
-
-
-
Brescia, Italië, 25123
- Actief, niet wervend
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan, Italië, 20133
- Werving
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390223904449
-
Naples, Italië, 80131
- Werving
- A.O.U. Federico II di Napoli ( Site 0435)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390817463660
-
Roma, Italië, 00168
- Werving
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390630155202
-
-
Torino
-
Orbassano, Torino, Italië, 10143
- Werving
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390119026534
-
-
-
-
Gelderland
-
Ede, Gelderland, Nederland, 6716 RP
- Werving
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
Contact:
- Study Coordinator
- Telefoonnummer: +31 318 435499
-
Nijmegen, Gelderland, Nederland, 6525 GA
- Werving
- UMC St. Radboud ( Site 0679)
-
Contact:
- Study Coordinator
- Telefoonnummer: +31 24 361 1111
-
-
Provincie Friesland
-
Drachten, Provincie Friesland, Nederland, 9202 NN
- Werving
- Nij Smellinghe ( Site 0684)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0512 588 888
-
-
-
-
-
Auckland, Nieuw-Zeeland, 1023
- Werving
- Auckland City Hospital ( Site 0831)
-
Contact:
- Study Coordinator
- Telefoonnummer: +6493074949
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 60-355
- Werving
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Werving
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-214
- Werving
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Polen, 75-581
- Werving
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48943488930
-
-
-
-
-
Madrid, Spanje, 28034
- Werving
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34913368263
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre ( Site 0622)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34608464547
-
Madrid, Spanje, 28040
- Werving
- Hospital Clinico San Carlos ( Site 0618)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34913303546
-
Seville, Spanje, 41013
- Werving
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat, Barcelona, Spanje, 08908
- Werving
- ICO L Hospitalet ( Site 0617)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34932607744
-
-
-
-
-
Taichung, Taiwan, 40705
- Werving
- Taichung Veterans General Hospital ( Site 0902)
-
Contact:
- Study Coordinator
- Telefoonnummer: +886423592525
-
Taipei, Taiwan, 11217
- Werving
- Taipei Veterans General Hospital ( Site 0901)
-
Contact:
- Study Coordinator
- Telefoonnummer: +886228712121
-
-
-
-
-
Adana, Turkije (Türkiye), 01250
- Werving
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903223271274
-
Ankara, Turkije (Türkiye), 06230
- Werving
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
Contact:
- Study Coordinator
- Telefoonnummer: +90 312 305 50 00
-
Ankara, Turkije (Türkiye), 06800
- Werving
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903125526000
-
Ankara, Turkije (Türkiye), 06620
- Werving
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903122126040
-
Istanbul, Turkije (Türkiye), 34010
- Werving
- Koç Üniversitesi Hastanesi ( Site 0656)
-
Contact:
- Study Coordinator
- Telefoonnummer: +905369410661
-
Istanbul, Turkije (Türkiye), 34098
- Werving
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
Contact:
- Study Coordinator
- Telefoonnummer: +902124143000
-
Rize, Turkije (Türkiye), 53020
- Werving
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
Contact:
- Study Coordinator
- Telefoonnummer: +904642130491
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 2QQ
- Werving
- Addenbrooke's Hospital ( Site 0747)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00441223216083
-
-
London, City of
-
London, London, City of, Verenigd Koninkrijk, NW3 2QG
- Werving
- Royal Free Hospital ( Site 0743)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00442077940500/2237
-
London, London, City of, Verenigd Koninkrijk, EC1A 7BE
- Werving
- St Bartholomew's Hospital ( Site 0749)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00442073777000
-
-
Surrey
-
London, Surrey, Verenigd Koninkrijk, SM3 5PT
- Werving
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0203 437 3500
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- UCLA Hematology & Oncology ( Site 0003)
-
Contact:
- Study Coordinator
- Telefoonnummer: 310-829-5471
-
Orange, California, Verenigde Staten, 92868
- Werving
- University of California-Irvine Medical Center ( Site 0016)
-
Contact:
- Study Coordinator
- Telefoonnummer: 714-456-5153
-
San Francisco, California, Verenigde Staten, 94158
- Werving
- UCSF Medical Center at Mission Bay ( Site 0034)
-
Contact:
- Study Coordinator
- Telefoonnummer: 415-502-2097
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Werving
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
Contact:
- Study Coordinator
- Telefoonnummer: 202-877-3061
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan ( Site 0021)
-
Contact:
- Study Coordinator
- Telefoonnummer: 734-936-4000
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
Contact:
- Study Coordinator
- Telefoonnummer: 347-798-8620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- Werving
- UPMC Hillman Cancer Center ( Site 0014)
-
Contact:
- Study Coordinator
- Telefoonnummer: 412-647-2811
-
-
Tennessee
-
Germantown, Tennessee, Verenigde Staten, 38138
- Werving
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
Contact:
- Study Coordinator
- Telefoonnummer: 901-683-0055
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center ( Site 0013)
-
Contact:
- Study Coordinator
- Telefoonnummer: 206-288-1111
-
-
-
-
-
Seoul, Zuid -Korea, 06351
- Werving
- Samsung Medical Center ( Site 0926)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82234103459
-
Seoul, Zuid -Korea, 03722
- Actief, niet wervend
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu, Seoul, Zuid -Korea, 05505
- Werving
- Asan Medical Center ( Site 0925)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82230105977
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
Experimenteel: Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
Andere namen:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
Experimenteel: I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Andere namen:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
Andere namen:
|
|
Experimenteel: I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Andere namen:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Tijdsspanne: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Tijdsspanne: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Tijdsspanne: Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Tijdsspanne: Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Tijdsspanne: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Tijdsspanne: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Tijdsspanne: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
Tijdsspanne: Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
Tijdsspanne: Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Tijdsspanne: Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
Tijdsspanne: Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Pathologische processen
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Neoplastische processen
- Pathologische aandoeningen, tekenen en symptomen
- Prostaatneoplasmata
- Neoplasma metastase
- Prostaatneoplasmata, castratiebestendig
- Organische chemicaliën
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Taxoids
- Cyclodecanes
- Diterpenen
- Docetaxel
- abirateron
- enzalutamide
Andere studie-ID-nummers
- 2400-01A
- MK-2400-01A (Andere identificatie: MSD)
- U1111-1310-5406 (Register-ID: UTN)
- IDeate-Prostate02 (Andere identificatie: MSD)
- 2024-516036-94-00 (Register-ID: EU CT)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .